← Back to Evidence Atlas
E3 PreliminaryPreliminaryPEM ?Reviewed
Standard · 3 min

Heat vs. Fatigue: Hyperthermia as a Possible Treatment Option for Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS).

Hochecker, Barbara, Matt, Katja, Scherer, Melanie et al. · International journal of molecular sciences · 2025 · DOI

Quick Summary

This small pilot study looked at how heat treatment (whole-body hyperthermia) affected immune cells from 9 people with ME/CFS. Researchers found that ME/CFS patients' cells showed signs of being overactive in certain ways compared to healthy people, and that heat treatment seemed to help normalize some of these cellular patterns. While these early results are promising, much larger studies are needed to confirm whether heat therapy could be a useful treatment.

Why It Matters

Understanding the cellular mechanisms underlying ME/CFS could help explain why patients experience fatigue and guide development of targeted treatments. If heat therapy can normalize abnormal cellular patterns in ME/CFS, this non-pharmacological approach might offer a new therapeutic option for a disease with limited evidence-based treatments.

Observed Findings

  • ME/CFS patients had higher baseline levels of LC3-II (an autophagy marker) compared to healthy controls.
  • Following a single whole-body hyperthermia session, LC3-II levels in ME/CFS patients decreased toward levels seen in healthy individuals.
  • Mitochondrial function parameters increased in ME/CFS patient cells after hyperthermia exposure.
  • Changes in these cellular markers occurred immediately after the heat treatment session.

Inferred Conclusions

  • Abnormal autophagy and mitochondrial function may be characteristic cellular features of ME/CFS.
  • Whole-body hyperthermia may help normalize dysregulated cellular processes in ME/CFS patients.
  • Heat-induced cellular normalization could be a potential mechanism underlying previously reported clinical benefits of hyperthermia in ME/CFS.

Remaining Questions

  • Do these acute cellular changes persist over days or weeks, or do they return to baseline?
  • Do the observed cellular improvements correlate with symptom improvement or functional gains in patients?
  • Would repeated hyperthermia sessions produce cumulative benefits or cause adverse effects?
  • Can these findings be replicated in a larger, properly controlled clinical trial with long-term follow-up?

What This Study Does Not Prove

This pilot study does not prove that whole-body hyperthermia is an effective clinical treatment for ME/CFS—it only shows acute cellular changes in laboratory conditions. The study cannot establish whether these cellular changes translate to symptom improvement, how long effects persist, or whether repeated treatments would be beneficial or safe. Results from 9 patients require validation in larger, controlled clinical trials before clinical recommendations can be made.

Topics

Immune Dysregulation

Tags

Method Flag:EXPLORATORYPEM_UNCLEAR

Metadata

DOI
10.3390/ijms26115339
PMID
40508148
Review status
Editor reviewed
Evidence level
Early hypothesis, preprint, editorial, or weak support
Last updated
7 April 2026